MedTrace Logo

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

NCT01944839 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 619

Last updated 2024-10-30

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

E10030

DRUG

ranibizumab

DRUG

E10030 sham intravitreal injection

Pressure on the eye with a syringe with no needle

Sponsors & Collaborators

  • Ophthotech Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Czechia
  • Estonia
  • Italy
  • Latvia
  • Poland
  • Slovakia
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01944839 on ClinicalTrials.gov